Guillain-Barre Syndrome Market Research Report, by Type (AIDP, MFS, AMAN), by Diagnosis (Lumbar Puncture), by Treatment (Plasmapheresis, Medication, Physical Therapy, Hydrotherapy), and by End-User (Hospitals, Diagnostic Centers) - Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Guillain-Barre Syndrome Market, by Type

6.1 Introduction

6.2 Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)

Market Estimates & Forecast, 2020–2027

6.3 Miller Fisher syndrome (MFS)

Market Estimates & Forecast, 2020–2027

6.3 Acute Motor Axonal Neuropathy (AMAN)

Market Estimates & Forecast, 2020–2027

6.4 Others

Chapter 7. Global Guillain-Barre Syndrome Market, by Diagnosis

7.1 Introduction

7.2 Lumbar Puncture

Market Estimates & Forecast, 2020–2027

7.3 Electromyography

Market Estimates & Forecast, 2020–2027

7.3.1 Intramuscular EMG

7.3.1 Surface EMG

7.4 Nerve Conduction Studies

Market Estimates & Forecast, 2020–2027

7.5 Others

Chapter 8. Global Guillain-Barre Syndrome Market, by Treatment

8.1 Introduction

8.2 Plasmapheresis

Market Estimates & Forecast, 2020–2027

8.3 Medication

Market Estimates & Forecast, 2020–2027

8.3.1 Privigen Intravenous

8.3.2 Gammagard Liquid Injection

8.3.3 Flebogamma DIF Intravenous

8.3.4 Bivigam Intravenous

8.4 Physical Therapy

Market Estimates & Forecast, 2020–2027

8.5 Hydrotherapy

Market Estimates & Forecast, 2020–2027

8.6 Others

Chapter 9. Global Guillain-Barre Syndrome Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

9.4 Others

Chapter 10. Global Guillain-Barre Syndrome Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Grifols

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Baxter

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 CSL Behring

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Akari Therapeutics Plc

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 ANNEXON, INC.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Curavac

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Hansa Medical

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Vitality Biopharma

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Covidien Limited

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Natus Medical Inc.

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Electrical Geodesics Inc.

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Guillain-Barre Syndrome Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Guillain-Barre Syndrome Industry Synopsis, 2020–2027

Table 2 Global Guillain-Barre Syndrome Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Guillain-Barre Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 5 Global Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million

Table 8 North America Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 9 North America Guillain-Barre Syndrome, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Guillain-Barre Syndrome, by Treatment, 2020–2027, (USD Million)

Table 11 North America Guillain-Barre Syndrome, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 13 U.S. Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 15 U.S. Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 21 South America Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 40 Middle East & Africa Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 41 Middle East & Africa Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 Middle East & Africa Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Guillain-Barre Syndrome Market

Figure 3 Market Dynamics for Global Guillain-Barre Syndrome Market

Figure 4 Global Guillain-Barre Syndrome Market Share, by Type 2020

Figure 5 Global Guillain-Barre Syndrome Market Share, by Diagnosis 2020

Figure 6 Global Guillain-Barre Syndrome Market Share, by Treatment, 2020

Figure 7 Global Guillain-Barre Syndrome Market Share, by End-User, 2020

Figure 8 Global Guillain-Barre Syndrome Market Share, by Region, 2020

Figure 9 North America Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 10 Europe Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 11 Asia Pacific Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 12 The Middle East & Africa Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 13 Global Guillain-Barre Syndrome Market: Company Share Analysis, 2020 (%)

Figure 14 Grifols: Key Financials

Figure 15 Grifols: Segmental Revenue

Figure 16 Grifols: Geographical Revenue

Figure 17 Baxter: Key Financials

Figure 18 Baxter: Segmental Revenue

Figure 19 Baxter: Geographical Revenue

Figure 20 CSL Behring: Key Financials

Figure 21 CSL Behring: Segmental Revenue

Figure 22 CSL Behring: Geographical Revenue

Figure 23 Akari Therapeutics Plc: Key Financials

Figure 24 Akari Therapeutics Plc: Segmental Revenue

Figure 25 Akari Therapeutics Plc: Geographical Revenue

Figure 26 ANNEXON, INC.: Key Financials

Figure 27 ANNEXON, INC.: Segmental Revenue

Figure 28 ANNEXON, INC.: Geographical Revenue

Figure 29 Curavac: Key Financials

Figure 30 Curavac: Segmental Revenue

Figure 31 Curavac: Geographical Revenue

Figure 32 Hansa Medical: Key Financials

Figure 33 Hansa Medical: Segmental Revenue

Figure 34 Hansa Medical: Geographical Revenue

Figure 35 Vitality Biopharma: Key Financials

Figure 36 Vitality Biopharma: Segmental Revenue

Figure 37 Vitality Biopharma: Geographical Revenue

Figure 38 Covidien Limited: Key Financials

Figure 39 Covidien Limited: Segmental Revenue

Figure 40 Covidien Limited: Geographical Revenue

Figure 41 Natus Medical Inc.: Key Financials

Figure 42 Natus Medical Inc.: Segmental Revenue

Figure 43 Natus Medical Inc.: Geographical Revenue

Figure 41 Electrical Geodesics Inc.: Key Financials

Figure 42 Electrical Geodesics Inc.: Segmental Revenue

Figure 43 Electrical Geodesics Inc.: Geographical Revenue